AR105199A1 - Soluciones oftálmicas acuosas - Google Patents
Soluciones oftálmicas acuosasInfo
- Publication number
- AR105199A1 AR105199A1 ARP160101981A ARP160101981A AR105199A1 AR 105199 A1 AR105199 A1 AR 105199A1 AR P160101981 A ARP160101981 A AR P160101981A AR P160101981 A ARP160101981 A AR P160101981A AR 105199 A1 AR105199 A1 AR 105199A1
- Authority
- AR
- Argentina
- Prior art keywords
- aqueous ophthalmic
- ophthalmic solution
- concentration
- chlorhexidine
- salt
- Prior art date
Links
- 239000002997 ophthalmic solution Substances 0.000 title abstract 11
- 229940054534 ophthalmic solution Drugs 0.000 abstract 10
- 229960003260 chlorhexidine Drugs 0.000 abstract 9
- -1 chlorhexidine compound Chemical class 0.000 abstract 8
- 150000003839 salts Chemical class 0.000 abstract 6
- 239000002738 chelating agent Substances 0.000 abstract 2
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 abstract 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 abstract 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 abstract 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- G—PHYSICS
- G02—OPTICS
- G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
- G02C13/00—Assembling; Repairing; Cleaning
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Materials For Medical Uses (AREA)
Abstract
Una solución oftálmica acuosa que incluye dicuafosol o una sal del mismo en una concentración de entre 0,1 y 10% (p/v) y un compuesto de clorhexidina en una concentración de entre 0,0001 y 0,1% (p/v). Reivindicación 1: Una solución oftálmica acuosa caracterizada porque comprende dicuafosol o una sal de éste en una concentración de entre 0,1% y 10% (p/v) y un compuesto de clorhexidina en una concentración de entre 0,0001% y 0,1% (p/v). Reivindicación 2: La solución oftálmica acuosa del acuerdo con la reivindicación 1, caracterizada porque el compuesto de clorhexidina es el gluconato de clorhexidina. Reivindicación 8: La solución oftálmica acuosa de acuerdo con cualquiera de las reivindicaciones 1 a 7, caracterizada porque la concentración del dicuafosol o de la sal de este en la solución oftálmica es de 3% (p/v). Reivindicación 9: La solución oftálmica acuosa de acuerdo con cualquiera de las reivindicaciones 1 a 8, caracterizada porque también comprende un agente quelante. Reivindicación 10: La solución de acuerdo oftálmica acuosa de acuerdo con la reivindicación 9, caracterizada porque el agente quelante es el ácido etilendiaminotetraacético o una sal de éste. Reivindicación 18: Un método para prevenir una disminución en la proporción restante de un compuesto de clorhexidina en una solución oftálmica acuosa que comprende entre 0,1% y 10% (p/v) de dicuafosol o de una sal de este y un compuesto de clorhexidina, caracterizado porque comprende usar un compuesto de clorhexidina en una concentración de entre 0,0001% y 0,005% (p/v) para preparar la solución oftálmica acuosa. Reivindicación 19: Un método para estabilizar un compuesto de clorhexidina en una solución oftálmica acuosa que comprende entre 0,1% y 10% (p/v) de dicuafosol o de una sal de este y un compuesto de clorhexidina, caracterizado porque comprende controlar la concentración del compuesto de clorhexidina de manera tal que sea superior a 0,001% (p/v) e inferior a 0,1% (p/v).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014263003 | 2014-12-25 | ||
| JP2015114595 | 2015-06-05 | ||
| JP2016111473A JP6104433B2 (ja) | 2015-06-05 | 2016-06-03 | 水性点眼液 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR105199A1 true AR105199A1 (es) | 2017-09-13 |
Family
ID=56150716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160101981A AR105199A1 (es) | 2014-12-25 | 2016-06-29 | Soluciones oftálmicas acuosas |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10278985B2 (es) |
| JP (3) | JP6779614B2 (es) |
| KR (3) | KR102330736B1 (es) |
| AR (1) | AR105199A1 (es) |
| BR (1) | BR112017013841A2 (es) |
| CA (1) | CA2971689C (es) |
| EA (1) | EA034517B1 (es) |
| MX (1) | MX384935B (es) |
| MY (1) | MY182507A (es) |
| PH (1) | PH12017501096A1 (es) |
| SG (1) | SG11201705138QA (es) |
| TW (1) | TWI709405B (es) |
| WO (1) | WO2016104704A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY182507A (en) * | 2014-12-25 | 2021-01-25 | Santen Pharmaceutical Co Ltd | Aqueous ophthalmic solution |
| WO2016195073A1 (ja) * | 2015-06-05 | 2016-12-08 | 参天製薬株式会社 | 水性点眼液 |
| EP3305301B1 (en) * | 2015-06-05 | 2024-11-27 | Santen Pharmaceutical Co., Ltd. | Therapeutic agent for dry eye characterized by being to be dropped into eye of dry eye patient wearing soft contact lens |
| MX2020008925A (es) * | 2018-02-28 | 2020-10-01 | Santen Pharmaceutical Co Ltd | Composicion oftalmica que comprende dicuafosol y polimero cationico. |
| JP6966667B2 (ja) * | 2019-08-27 | 2021-11-17 | 参天製薬株式会社 | ジクアホソルまたはその塩、およびポリビニルピロリドンを含有する水性眼科用組成物 |
| US11229549B2 (en) * | 2019-09-18 | 2022-01-25 | Vance M. Thompson | Tear transplantation and multi-part contact lens with absorbent portion |
| CA3176584A1 (en) * | 2020-03-31 | 2021-10-07 | Santen Pharmaceutical Co., Ltd. | Silver salt-containing ophthalmic aqueous composition filled in resin container |
| KR102365008B1 (ko) * | 2020-06-23 | 2022-02-23 | 주식회사태준제약 | 디쿠아포솔을 포함하는 점안 조성물 |
| WO2021261930A1 (ko) * | 2020-06-23 | 2021-12-30 | 주식회사태준제약 | 디쿠아포솔을 포함하는 점안 조성물 |
| JP2022102757A (ja) * | 2020-12-25 | 2022-07-07 | ライオン株式会社 | 機械学習実行プログラム、ドライアイ検査プログラム、機械学習実行装置及びドライアイ検査装置 |
| KR102548710B1 (ko) | 2020-12-24 | 2023-06-28 | 주식회사 종근당 | 디쿠아포솔 또는 이의 약제학적으로 허용가능한 염과 토코페롤을 함유하는 건성안 예방 또는 치료용 약제학적 조성물 |
| JP7230169B2 (ja) * | 2020-12-25 | 2023-02-28 | 参天製薬株式会社 | ジクアホソルまたはその塩、銀塩およびイオン性等張化剤を含有する水性点眼液 |
| WO2024010040A1 (ja) * | 2022-07-06 | 2024-01-11 | ロート製薬株式会社 | 眼科組成物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09301858A (ja) | 1996-05-13 | 1997-11-25 | Senju Pharmaceut Co Ltd | グルコン酸クロルヘキシジン安定化水性薬剤 |
| JPH10203960A (ja) * | 1997-01-24 | 1998-08-04 | Ofutekusu:Kk | 点眼液組成物 |
| JPH1160505A (ja) | 1997-05-20 | 1999-03-02 | Senju Pharmaceut Co Ltd | 防腐組成物 |
| JP2008222638A (ja) | 2007-03-13 | 2008-09-25 | Teika Seiyaku Kk | 油成分含有眼用組成物 |
| JP2009073788A (ja) | 2007-09-21 | 2009-04-09 | Teika Seiyaku Kk | イソプロピルウノプロストン含有眼用組成物 |
| JP5398452B2 (ja) * | 2008-09-30 | 2014-01-29 | 大正製薬株式会社 | 点眼剤 |
| JP5639409B2 (ja) * | 2009-08-07 | 2014-12-10 | ロート製薬株式会社 | シリコーンハイドロゲルコンタクトレンズ用眼科組成物 |
| JP6047272B2 (ja) * | 2010-09-15 | 2016-12-21 | テイカ製薬株式会社 | 角膜上皮障害治療用点眼剤 |
| MY161032A (en) * | 2010-12-28 | 2017-04-03 | Santen Pharmaceutical Co Ltd | Ophthalmic solution comprising diquafosol, method for producing the same, and method for inhibiting formation of insoluble precipitate |
| BR112014023402B1 (pt) | 2012-03-26 | 2020-09-29 | Santen Pharmaceutical Co., Ltd | Solução oftálmica compreendendo diquafosol e métodos para produção da mesma, para inibição da formação dos precipitados insolúveis na mesma, para redução da irritação ocular causada pela mesma e para aumentar a eficácia de conservação da mesma |
| MY182507A (en) * | 2014-12-25 | 2021-01-25 | Santen Pharmaceutical Co Ltd | Aqueous ophthalmic solution |
-
2015
- 2015-12-25 MY MYPI2017000969A patent/MY182507A/en unknown
- 2015-12-25 US US15/539,283 patent/US10278985B2/en active Active
- 2015-12-25 TW TW104143787A patent/TWI709405B/zh active
- 2015-12-25 KR KR1020187015734A patent/KR102330736B1/ko active Active
- 2015-12-25 BR BR112017013841-7A patent/BR112017013841A2/pt not_active Application Discontinuation
- 2015-12-25 EA EA201791467A patent/EA034517B1/ru not_active IP Right Cessation
- 2015-12-25 KR KR1020177029478A patent/KR101867791B1/ko active Active
- 2015-12-25 CA CA2971689A patent/CA2971689C/en active Active
- 2015-12-25 JP JP2015253360A patent/JP6779614B2/ja active Active
- 2015-12-25 KR KR1020177014598A patent/KR101789019B1/ko active Active
- 2015-12-25 MX MX2017008277A patent/MX384935B/es unknown
- 2015-12-25 WO PCT/JP2015/086230 patent/WO2016104704A1/ja not_active Ceased
- 2015-12-25 SG SG11201705138QA patent/SG11201705138QA/en unknown
-
2016
- 2016-06-29 AR ARP160101981A patent/AR105199A1/es unknown
-
2017
- 2017-06-13 PH PH12017501096A patent/PH12017501096A1/en unknown
-
2019
- 2019-03-13 US US16/351,661 patent/US10786526B2/en not_active Expired - Fee Related
-
2020
- 2020-10-14 JP JP2020173120A patent/JP7128243B2/ja active Active
-
2022
- 2022-08-18 JP JP2022130503A patent/JP2022166223A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EA201791467A1 (ru) | 2017-11-30 |
| US20190209599A1 (en) | 2019-07-11 |
| JP2021008513A (ja) | 2021-01-28 |
| MY182507A (en) | 2021-01-25 |
| US20170348344A1 (en) | 2017-12-07 |
| CA2971689A1 (en) | 2016-06-30 |
| TW201628626A (zh) | 2016-08-16 |
| KR20170067900A (ko) | 2017-06-16 |
| KR101789019B1 (ko) | 2017-10-20 |
| BR112017013841A2 (pt) | 2018-06-19 |
| TWI709405B (zh) | 2020-11-11 |
| KR20170118255A (ko) | 2017-10-24 |
| JP2022166223A (ja) | 2022-11-01 |
| WO2016104704A1 (ja) | 2016-06-30 |
| JP7128243B2 (ja) | 2022-08-30 |
| PH12017501096A1 (en) | 2017-11-27 |
| MX384935B (es) | 2025-03-14 |
| JP6779614B2 (ja) | 2020-11-04 |
| SG11201705138QA (en) | 2017-07-28 |
| KR20180063381A (ko) | 2018-06-11 |
| KR102330736B1 (ko) | 2021-11-23 |
| JP2016210759A (ja) | 2016-12-15 |
| MX2017008277A (es) | 2017-10-02 |
| EA034517B1 (ru) | 2020-02-17 |
| CA2971689C (en) | 2020-11-03 |
| US10278985B2 (en) | 2019-05-07 |
| KR101867791B1 (ko) | 2018-06-15 |
| US10786526B2 (en) | 2020-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR105199A1 (es) | Soluciones oftálmicas acuosas | |
| MX2018005829A (es) | Composiciones para tratar el cabello. | |
| MX2017013590A (es) | Administracion de agente anticaspa soluble en surfactante. | |
| ES2601137T3 (es) | Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido | |
| BR112018075140A2 (pt) | composição na forma de uma solução aquosa injetável, e, formulação de dose única a um ph de 7 a 7,8 | |
| MX2019002781A (es) | Estabilizadores de mastocitos para el tratamiento de hipercitoquinemia e infeccion viral. | |
| WO2016094834A3 (en) | A method for treating a complement mediated disorder caused by an infectious agent in a patient | |
| MX2016013154A (es) | Composicion que contiene peroxido y acido peracetico y proceso para matar esporas. | |
| EA201891783A1 (ru) | Композиция для растворения аморфных дитиазинов и способ ее применения | |
| PH12017500512B1 (en) | Electrode for electrochlorination processes and method of manufacturing thereof | |
| MX2018007112A (es) | Composicion de peroximonosulfato de disolucion rapida. | |
| CO2017012645A2 (es) | Agente antihipertensivo que comprende s-1-propenilcisteína o una sal del mismo como ingrediente activo | |
| EA201990163A1 (ru) | Консервация микроорганизмов | |
| CL2018000452A1 (es) | Método y dispositivo de desinfección de superficies internas de congeladores y similares | |
| MX2016012248A (es) | Composiciones para el tratamiento de autodigestion. | |
| CO2017001902A2 (es) | Adyuvantes acondicionadores del agua que promueven una baja volatilidad | |
| NZ733329A (en) | Microbiocidal control in the processing of poultry | |
| MX2018004381A (es) | Combinacion que comprende un compuesto de aminotiolester o una de sus sales farmaceuticamente aceptables y un compuesto capaz de aumentar el nivel de peroxido de hidrogeno (h2o2) en las celulas cancerosas de un sujeto. | |
| MX345216B (es) | Solucion oftalmica que contiene acido hialuronico o sal del mismo y propilenglicol. | |
| MX378402B (es) | Composiciones para aplicaciones topicas que comprenden peroxido de benzoilo y adapaleno. | |
| MX2016011572A (es) | Composiciones antimicrobianas de acido organico. | |
| MX365973B (es) | Barras de limpieza con taurina. | |
| ES2721003T3 (es) | Utilización de ácido 1, 3 - propano disulfónico o sales farmacéuticamente aceptables del mismo para el tratamiento de la sarcoidosis | |
| AR115471A1 (es) | Composiciones conservadas | |
| MX2016012623A (es) | Combinacion de adapaleno y peroxido de benzoilo para tratar cicatrices de acne. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |